Board of Directors

ANNIE CHENG, CFA

Director of Corporate Development

Annie joined the company in May 2013. Annie has 14 years of experience in the healthcare industry, in equity research and consulting. While in equity research, Annie covered a wide range of European and U.S. healthcare stocks with a diverse range of market capitalization, business models, and therapeutic focus. Annie moved to London with JPMorgan when she transferred from the US Large Cap Pharma research team in New York to lead the European Biotechnology research efforts in London. After JPMorgan, Annie worked in research for boutique banks and was involved in fundraisings for small European healthcare companies totalling over €200 million. Annie then founded a consultancy where she advised a number of biotechnology companies in corporate development and communications with the investor community.

TIM FREEBORN BA ACA

Finance Director and Company Secretary

Tim joined the company in August 2012 and became full time in October. Previously he was head of research at Xcap Securities and an analyst at Evolution Securities. After qualifying as a chartered accountant he left practice to become a journalist. For 12 years he worked in the Daily Mail City Office covering biotech, electronics and real estate. Tim gained a BA in Philosophy at University College London. He is 53.

MIKE KHAN

Non-Executive Director

Dr Michael Khan BSc, MBBS, PhD, FRCP is an Associate Professor of Medicine at the University of Warwick and a Consultant Physician at University Hospitals. He trained in medicine at Guy's and King's in London and completed specialist training at University College London, Middlesex and Whittington Hospitals. He studied for his PhD at UCL. He is a highly cited researcher and experienced clinician with a long track record in metabolic medicine and cancer biology research as well as in the running of clinical trials. He has written several books on diabetes, cholesterol problems and cancer biology and teaches postgraduates and undergraduates in medicine and biological sciences in these areas. He is a previous Head of Molecular Medicine at Warwick University and has held numerous research grants in cell and molecular biology. He and co-workers have made important contributions to further understanding of cancer cell biology and diabetes and are working on identifying novel tissue-based biomarkers for colorectal cancer and the development of novel diagnostic tools. He is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART-UK and Diabetes UK and has acted as an expert advisor to numerous National and International Organisations in both the public and private sectors.

DAVID MACK, Ph.D

Non-Executive Director

Dr. Mack is a director at Alta Partners where he led the investment in Angiosyn as a director and acting CEO (acquired by Pfizer in 2005). He joined Intradigm’s board in May 2006 and served on that board until the merger with Silence Therapeutics. He is currently on the board of directors of Aerie Pharmaceuticals, Ceregene and Proacta. Prior to Alta, Dr. Mack co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1995 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. He was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s. Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science and Nature, and he is an inventor on 21 US patents. He was an American Cancer Society postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology. Dr. Mack received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes fellow in Molecular Genetics and Cell Biology. He holds a Bachelor of Arts in Molecular Biology from University of California, Berkeley.

ALI MORTAZAVI

Chief Executive

Ali Mortazavi joined Silence in August 2012 as director of corporate strategy and became chief executive in May 2013. He engineered two fundraisings last year to raise £11m for the company and spearheaded the £19m placing completed in April 2013. He has over 17 years of in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm, leaving in 2008. He has extensive experience in small companies and has had significant stakes in UK listed technology/biotech ventures.

JERRY RANDALL

Executive Chairman

Mr. Randall is a qualified chartered accountant and previously served as the chief financial officer of Sinclair Pharmaceuticals plc which he joined in 2000 as part of a management buy-in team. Prior to this, Mr. Randall worked in corporate finance with Gambit Corporate Finance and had previously been involved in two other buy-ins. He acted as adviser to both private and quoted companies between 1993 and 2000, in both the capacity of nominated adviser and in practice with KPMG. During this period, he was involved in a number of flotations and transactions on the Official List, Unlisted Securities Market and the Alternative Investment Market, as well as raising private equity.